Kathryn Shah

Kathryn (Coleman) Shah, MBA, PMP, currently serves as the Senior Vice President of Portfolio and Program Management at Candid Therapeutics since August 2024. Prior experience includes roles such as Vice President and Head of Program Management at RayzeBio, and Senior Director of Program Management at Ultragenyx Pharmaceutical Inc., where responsibility involved leading cross-functional teams and managing program activities. Previously, Kathryn held various positions at AbbVie, including Program Director, focusing on regulatory approvals and budget management exceeding $150 million. Additional experience includes significant roles at Abbott Laboratories and Johnson & Johnson, with a solid foundation in technical and operational management gained during earlier positions at HB Fuller. Kathryn holds an MBA from HEC Paris and a Bachelor of Science in Chemistry from Virginia Tech.